biote (BTMD) risk factors
Item 1A of every biote Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors66 risks9 new7 dropped22 reworded
Biote expanded disclosures on supply chain reliance, tariffs, inventory management, restructuring, and commercial agreements. The company added new risks regarding trade policies affecting material sourcing like estradiol from China and trocars from Pakistan. Disclosures now reflect the acquisition of Asteria Health and the termination notice from partner AnazaoHealth.
Filed Mar 13, 2026 - FY2024 10-K risk factors64 risks
Revenue heavily concentrates in ten southern states, making operations vulnerable to regional disruptions. Reliance on specific third-party compounding pharmacies creates supply chain vulnerability. International expansion into Latin America introduces lower margin profiles and distribution risks.
Filed Mar 14, 2025